Afraxis Inc., of San Diego, named Carmine Stengone president and CEO, and Christopher Rex chief scientific officer...Cleveland BioLabs Inc., of Buffalo, N.Y., added Julia Brown and Anthony Principi to its board, and appointed David Hohn board chairman

Aeterna Zentaris Inc., of Quebec City, appointed David A. Dodd president and CEO...Astellas Pharma Inc., of Tokyo, named Songlin Xue head of global pharmacovigilance, and he will be based in the Northbrook, Ill., office...Zosano Pharma Inc., of Fremont, Calif., named Chris Krueger chief business officer and added Kleanthis G. Xanthopoulos to its board

Bristol-Myers Squibb Co., of New York, named Francis Cuss executive vice president and chief scientific officer, effective July 1...EntreMed Inc., of Rockville, Md., appointed Ken K. Ren CEO, and added James Huang and Y. Alexander Wu to its board

F2G Ltd., of Manchester, UK, appointed Ian Nicholson CEO and board member...NeuroVive Pharmaceutical AB, of Lund, Sweden, elected Anna Malm Bernsten and Boel Flodgren to its board...Vermillion Inc., of Austin, Texas, appointed Thomas McLain president and CEO

Champions Oncology Inc., of Hackensack, N.J., added Dan Mendelson and Arthur G...Cytori Therapeutics Inc., of San Diego, named Steven Kesten executive vice president and chief medical officer...OncoSec Medical Inc., of San Diego, appointed Sanjiv S. Agarwala, Axel Hauschild, Kim A. Margolin and Vernon K. Sondak to its new melanoma advisory board (MAB) and named Adil I. Daud chairman of the MAB

Protea Biosciences Inc., of Morgantown, W. Va., added Thijs Spoor and Josiah T. Austin to its board...Regulus Therapeutics Inc., of La Jolla, Calif., added Mark G. Foletta to its board and audit committee...Soligenix Inc., of Princeton, N.J., appointed Stephen T. Sonis, Dorothy Keefe and Mark Schubert to its newly created medical advisory board, which will deal with SGX942, its treatment for oral mucositis

CytoDyn Inc., of Portland, Ore., named Michael D. Mulholland chief financial officer, treasurer and corporate secretary, and added Michael Nobel and Allan Green to its board...GeNO LLC, of Waltham, Mass., named Kurt Dasse president and Barry Gellman senior vice president, engineering...IntelliCell BioSciences Inc., of New York, appointed Harry Fisch director of urology and added him to its scientific advisory board

Five Prime Therapeutics Inc., of South San Francisco, appointed Julie Hambleton senior vice president and chief medical officer...ImmunoCellular Therapeutics Ltd., of Los Angeles, named Andrew Gengos president and CEO...Pluristem Therapeutics Inc., of Haifa, Israel, appointed Fred Appelbaum, Richard Champlin, Edwin M. Horwitz, Hillard M. Lazarus, Reuven Or and Jacob M. Rowe to its hematology clinical advisory board

Summit plc, of Oxford, UK, added Jim Mellon and Frank Armstrong to its board...and Justin Smith senior vice president, general manager, U.S. Rx dermatology...Verastem Inc., of Cambridge, Mass., added Alison Lawton and Michael Kauffman to its board

Alimera Sciences Inc., of Atlanta, appointed Philip Ashman senior vice president and European managing director and named Eric Teo vice president and European medical director...Anne-Marie Swift will serve as vice president and European marketing director...Ohr Pharmaceuticals Inc., of New York, added Jeffrey S. Heier and Daniel Roth to its scientific advisory board

Blueprint Medicines, of Cambridge, Mass., appointed Chris Varma president and CEO, and named Daniel S. Lynch executive chairman of its board...HemoShear LLC, of Charlottesville, Va., added Mehmood Khan and Frederick W.K. Brown to its board

DCPrime BV, of Amsterdam, the Netherlands, named Marcel Zwaal CEO and Anthony Hall chief medical officer...Theratechnologies Inc., of Montreal, appointed Luc Tanguay interim president and CEO...Zyngenia Inc., of Gaithersburg, Md., added Christian Itin and Jason Rhodes to its board

Althea Technologies Inc., of San Diego, named Rick Hancock president and CEO, Chris Duffy senior vice president of operations and E.J. Brandreth senior vice president of quality and regulatory...SpringLeaf Therapeutics Inc., of Boston, appointed Pieter Muntendam president and CEO

Eli Lilly and Co., of Indianapolis, named Michael Harrington senior vice president and general counsel...Vertex Pharmaceuticals Inc., of Cambridge, Mass., appointed Stuart Arbuckle executive vice president and chief commercial officer

Actinium Pharmaceuticals Inc., of New York, hired Jack V. Talley as president and CEO and added Enza Guagenti as chief financial officer...BioMotiv LLC, of Cleveland, named Baiju R. Shah CEO and board member, effective Sept...ImmunoCellular Therapeutics Ltd., of Los Angeles, named John S. Yu interim CEO and president

he will chair the audit committee and serve on the compensation committee...Dynavax Technologies Corp., of Berkeley, Calif., named Christine Larson vice president and chief financial officer...Nile Therapeutics Inc., of San Mateo, Calif., named Darlene Horton president and CEO, and director

Caisson Biotech LLC, of Austin, Texas, appointed Glenn Nedwin CEO and president...Quanterix Corp., of Lexington, Mass., named Paul Chapman president and CEO...RXi Pharmaceuticals Corp., of Westborough, Mass., added Jeannette Graf and Leroy Young to its scientific advisory board

NovImmune SA, of Plan-Les-Ouates, Switzerland, added Michael Steinmetz to its board and appointed David Slack head of corporate and business development...Savient Pharmaceuticals Inc., of East Brunswick, N.J., appointed Louis Ferrari president and CEO...Xenetic Biosciences plc, of London, added Subash Kapre and Thomas Ulich to its scientific advisory board

Akshay Vaishnaw executive vice president and chief medical officer...and Thomas Rollins senior vice president of program and portfolio management